Cite
APA Citation
Bruni, C., Gentileschi, S., Pacini, G., Bardelli, M., Tofani, L., Bartoli, F., Baldi, C., Cometi, L., Fiori, G., Nacci, F., Cantarini, L., Guiducci, S., Moggi-Pignone, A., Frediani, B., & Matucci-Cerinic, M. (2021). switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic advances in musculoskeletal disease, 13, . http://access.bl.uk/ark:/81055/vdc_100141093846.0x0000cf